DIRECT ORAL ANTICOAGULANTS
Several direct oral anticoagulants (DOACs), namely, apixaban, rivaroxaban, and dabigatran etexilate, are currently licensed in Europe and the United States for various thromboembolic indications. They provide alternatives to low molecular weight heparin in a peri-operative setting for venous thrombo...
Saved in:
| Main Authors: | I. Tzoran, B. Brenner |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2016-06-01
|
| Series: | Акушерство, гинекология и репродукция |
| Subjects: | |
| Online Access: | https://www.gynecology.su/jour/article/view/32 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact on Adherence and Clinical Outcomes of an Anticoagulation Stewardship Program in Users of Direct Oral Anticoagulants
by: Mayra A. Arenas-Beltrán, et al.
Published: (2025-04-01) -
The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
by: К. V. Lobastov, et al.
Published: (2020-05-01) -
Evaluation of extended direct oral anticoagulant dosing strategies in patients with and without cancer from a prospective observational registry
by: Danielle T. Vlazny, et al.
Published: (2025-05-01) -
Temporal Changes in Long‐Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era
by: Kazuhisa Kaneda, et al.
Published: (2024-08-01) -
Problematic points of anticoagulant therapy for atrial fibrillation in certain Russian regions in 2016- 2019: results of a retrospective big data analysis
by: M. A. Druzhilov, et al.
Published: (2024-10-01)